The report for Global Serotonin Syndrome Market by Market Research Future comprises of
extensive primary research along with the detailed analysis of qualitative as well as
quantitative aspects by various industry experts, key opinion leaders to gain a deeper
insight of the market and industry performance.
The Serotonin Syndrome Market is expected to reach $ 400 million by the end of 2023, this
market is projected to growing at a CAGR of ~ 2.3 % during 2017-2023.
Serotonin syndrome is a group of symptoms such as high body temperature, agitation,
increased reflexes, tremor, sweating, dilated pupils, diarrhoea etc. due to use of
serotonergic drugs. Serious complications such as seizures and extensive muscle breakdown
may occur which may lead to death. The 1984, Libby Zion case is an example of death from
serotonin syndrome. Serotonin syndrome is typically caused by synergistic effect of two or
more serotonergic drugs which generally include selective serotonin reuptake inhibitor
(SSRI), serotonin norepinephrine reuptake inhibitor (SNRI), monoamine oxidase inhibitor
(MAOI), tricyclic antidepressants (TCAs), amphetamines etc. Other drugs with a high
propensity of causing serotonin syndrome are dextromethorphan, buspirone, L-tryptophan,
St. John's wort, metoclopramide, ondansetron etc. There is no laboratory test to confirm the
diagnosis of serotonin syndrome.
The treatment for serotonin syndrome consists of discontinuing medications contributing to
the condition. For serious cases, other treatments for managing associated symptoms may
be used. For serious cases with a threat to life gastrointestinal decontamination using
activated charcoal is performed. Sedatives such as benzodiazepines are used for agitated
patients. High fever is a common symptom of serotonin syndrome which reaches extremely
high temperatures greater than forty centigrade. To control hyperthermia cooling measures
may be needed. Serotonin antagonist such as cyproheptadine may be needed.
The market restraints are the low number of cases and equally low number of fatalities
associated with the syndrome with less than 1% cases consuming serotonin syndrome
causing drugs developing the diseases. Mild symptoms occur in about 15% of SSRI
overdoses.
Segments:
The global serotonin syndrome market is segmented on the basis of drug treatment, and
end users. Based on drug treatment, the market has been segmented as serotonin
antagonists, supportive care (Muscle relaxants, the control of autonomic instability, anti-
hyperthermics, antihypertensive and others. Based on the end users, the market has been
segmented as hospitals, point of care and others.
Key players of Global Serotonin syndrome market:
Key players profiled in the report are AstraZeneca Plc., Eli Lilly and Company, Forest